DEFA14A: Ginkgo Bioworks Announces Board Nominations: Myrtle Potter and Ross Fubini to Join, Dekkers and Kewalramani to Retire

Ginkgo Bioworks nominates Myrtle Potter and Ross Fubini as independent directors while Marijn Dekkers and Reshma Kewalramani will retire from the board at the upcoming annual meeting on June 13, 2024.

Summary

• Ginkgo Bioworks has nominated Myrtle Potter and Ross Fubini to its Board of Directors.
• The election will take place at the annual meeting scheduled for June 13, 2024.
• Marijn Dekkers and Reshma Kewalramani will not stand for reelection and will retire from the Board.
• Myrtle Potter brings over 25 years of experience in the life sciences and technology sectors, including roles at Sumitomo Pharma America, Roivant Sciences, Genentech, Bristol-Myers Squibb, and Merck.
• Ross Fubini is the founder of XYZ Venture Capital and has experience advising and investing in over 200 companies.
• He has also held operating roles at CubeTree, Symantec, and Plumtree Software.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the addition of experienced board members. The departure of existing members is presented as a natural transition.

Positives

• The addition of Myrtle Potter brings significant experience in the pharmaceutical R&D value chain and AI application.
• Ross Fubini's expertise in defense tech and venture capital could provide valuable insights for Ginkgo's growth.
• The new board members could bring fresh perspectives and expertise to guide Ginkgo's strategic direction.

Negatives

• The departure of Marijn Dekkers and Reshma Kewalramani means the loss of their experience and leadership on the board.

Risks

• The forward-looking statements in the release are subject to various risks and uncertainties, including market volatility, competition, and regulatory changes.
• The company's ability to achieve its business plans and realize additional opportunities is not guaranteed.
• There are risks associated with demand for synthetic biology products, biosecurity services, and the success of the Foundry platform programs.

Future Outlook

The company anticipates a new phase of transformation and growth with the addition of the new board members.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo, expressed excitement about the new board nominees and gratitude to the retiring members.
• Jason Kelly stated that Myrtle Potter brings a wealth of experience across the pharmaceutical R&D value chain.
• Jason Kelly stated that Ross Fubini brings deep knowledge of the defense tech landscape.

Industry Context

The announcement reflects a trend of companies seeking board members with expertise in emerging technologies like AI and defense tech, aligning with Ginkgo's focus on cell programming and biosecurity.

Comparison to Industry Standards

• Ginkgo's board composition changes are similar to other publicly traded biotech companies that regularly refresh their boards to bring in new expertise.
• The addition of individuals with venture capital backgrounds, like Ross Fubini, is common in growth-oriented companies to provide guidance on fundraising and strategic partnerships.
• Myrtle Potter's experience at large pharmaceutical companies like Genentech and Bristol-Myers Squibb aligns with industry standards for board members in the biotech sector.

Management Changes

Stakeholder Impact

• Shareholders will have the opportunity to vote on the new board members.
• Employees may be impacted by the strategic direction set by the new board.
• Customers and partners could benefit from the expertise and insights of the new board members.

Next Steps

• Shareholders will vote on the election of the new directors at the annual meeting on June 13, 2024.

Key Dates

Keywords

Ginkgo Bioworks, Board of Directors, Myrtle Potter, Ross Fubini, Annual Meeting, Director Nomination, Biosecurity, Cell Programming, Synthetic Biology